Oncotelic Therapeutics, Inc. (OTLC)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.16 Million USD | 88.85% |
| 2022 | -5.59 Million USD | 44.13% |
| 2021 | -9.06 Million USD | -25.54% |
| 2020 | -7.6 Million USD | -69.89% |
| 2019 | -4.25 Million USD | -30.77% |
| 2018 | -678.54 Thousand USD | 76.51% |
| 2017 | -13.8 Million USD | -0.68% |
| 2016 | -13.63 Million USD | -0.36% |
| 2015 | -13.63 Million USD | -8.2% |
| 2014 | -12.53 Million USD | -52.76% |
| 2013 | -8.16 Million USD | -3.09% |
| 2012 | -7.95 Million USD | 31.2% |
| 2011 | -9.5 Million USD | 4.49% |
| 2010 | -23.57 Million USD | 60.81% |
| 2009 | -28.72 Million USD | -7.19% |
| 2008 | -21.69 Million USD | -32.38% |
| 2007 | -20.17 Million USD | -8.92% |
| 2006 | -15.27 Million USD | -43.75% |
| 2005 | -11.76 Million USD | -29.91% |
| 2004 | -9.89 Million USD | -11.82% |
| 2003 | -8.71 Million USD | 27.88% |
| 2002 | -12.06 Million USD | -401.09% |
| 2001 | -3.22 Million USD | 75.98% |
| 2000 | -11.13 Million USD | 4.95% |
| 1999 | -11.71 Million USD | 23.41% |
| 1998 | -13.43 Million USD | -23.39% |
| 1997 | -10.24 Million USD | -72.22% |
| 1996 | -6.5 Million USD | -63.64% |
| 1995 | -4 Million USD | -57.14% |
| 1994 | -2.8 Million USD | -40.0% |
| 1993 | -2 Million USD | -33.33% |
| 1992 | -1.5 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -167.22 Thousand USD | 71.34% |
| 2024 Q2 | -96.58 Thousand USD | 62.59% |
| 2023 Q4 | -113.46 Thousand USD | -883.67% |
| 2023 FY | - USD | 88.85% |
| 2023 Q3 | 14.47 Thousand USD | 107.18% |
| 2023 Q2 | -201.77 Thousand USD | -5.16% |
| 2023 Q1 | -191.87 Thousand USD | 47.55% |
| 2022 Q3 | -358.27 Thousand USD | 97.93% |
| 2022 Q4 | -365.78 Thousand USD | -2.1% |
| 2022 Q1 | -4.33 Million USD | -188.86% |
| 2022 Q2 | -17.33 Million USD | -300.12% |
| 2022 FY | - USD | 44.13% |
| 2021 Q4 | -1.49 Million USD | 16.4% |
| 2021 Q2 | -3.74 Million USD | -85.36% |
| 2021 FY | - USD | -25.54% |
| 2021 Q3 | -1.79 Million USD | 52.16% |
| 2021 Q1 | -2.02 Million USD | 37.59% |
| 2020 Q3 | -1.52 Million USD | -1554.4% |
| 2020 FY | - USD | -69.89% |
| 2020 Q1 | -2.55 Million USD | 8.61% |
| 2020 Q2 | 104.87 Thousand USD | 104.1% |
| 2020 Q4 | -3.24 Million USD | -112.48% |
| 2019 Q2 | -1.13 Million USD | -79.04% |
| 2019 Q1 | -634 Thousand USD | -0.79% |
| 2019 FY | - USD | -30.77% |
| 2019 Q4 | -2.79 Million USD | -204.89% |
| 2019 Q3 | -917.92 Thousand USD | 19.14% |
| 2018 Q4 | -629 Thousand USD | 7.5% |
| 2018 Q2 | -1.14 Million USD | -44.77% |
| 2018 FY | - USD | 76.51% |
| 2018 Q1 | -793 Thousand USD | 67.42% |
| 2018 Q3 | -680 Thousand USD | 40.77% |
| 2017 Q1 | -3.96 Million USD | -14.2% |
| 2017 FY | - USD | -0.68% |
| 2017 Q4 | -2.43 Million USD | 31.15% |
| 2017 Q3 | -3.53 Million USD | 9.22% |
| 2017 Q2 | -3.89 Million USD | 1.79% |
| 2016 Q3 | -3.25 Million USD | 11.11% |
| 2016 Q4 | -3.47 Million USD | -6.6% |
| 2016 FY | - USD | -0.36% |
| 2016 Q1 | -3.34 Million USD | 16.04% |
| 2016 Q2 | -3.66 Million USD | -9.5% |
| 2015 Q1 | -2.78 Million USD | -5.98% |
| 2015 Q4 | -3.98 Million USD | -10.66% |
| 2015 FY | - USD | -8.2% |
| 2015 Q2 | -3.33 Million USD | -19.77% |
| 2015 Q3 | -3.6 Million USD | -8.07% |
| 2014 Q3 | -3.45 Million USD | 11.81% |
| 2014 Q1 | -2.62 Million USD | -26.98% |
| 2014 FY | - USD | -52.76% |
| 2014 Q2 | -3.91 Million USD | -49.24% |
| 2014 Q4 | -2.62 Million USD | 24.05% |
| 2013 Q3 | -2.64 Million USD | -59.9% |
| 2013 Q1 | -1.88 Million USD | -15.74% |
| 2013 Q4 | -2.06 Million USD | 21.9% |
| 2013 Q2 | -1.65 Million USD | 12.01% |
| 2013 FY | - USD | -3.09% |
| 2012 FY | - USD | 31.2% |
| 2012 Q1 | -1.82 Million USD | 17.38% |
| 2012 Q2 | -2.29 Million USD | -25.86% |
| 2012 Q3 | -2.22 Million USD | 3.01% |
| 2012 Q4 | -1.62 Million USD | 26.86% |
| 2011 Q1 | -5.27 Million USD | -2.25% |
| 2011 FY | - USD | 4.49% |
| 2011 Q4 | -2.2 Million USD | -69.41% |
| 2011 Q3 | -1.3 Million USD | 54.0% |
| 2011 Q2 | -2.82 Million USD | 46.37% |
| 2010 FY | - USD | 60.81% |
| 2010 Q2 | -12.56 Million USD | -1644.72% |
| 2010 Q1 | -720 Thousand USD | 92.6% |
| 2010 Q3 | 6.26 Million USD | 149.88% |
| 2010 Q4 | -5.15 Million USD | -182.3% |
| 2009 Q3 | -8.53 Million USD | -1.82% |
| 2009 Q2 | -8.38 Million USD | -26.19% |
| 2009 FY | - USD | -7.19% |
| 2009 Q1 | -6.64 Million USD | 22.43% |
| 2009 Q4 | -9.72 Million USD | -13.93% |
| 2008 Q3 | -7.28 Million USD | 0.14% |
| 2008 Q1 | -5.97 Million USD | -32.51% |
| 2008 FY | - USD | -32.38% |
| 2008 Q4 | -8.56 Million USD | -17.6% |
| 2008 Q2 | -7.29 Million USD | -22.14% |
| 2007 Q4 | -4.5 Million USD | 26.48% |
| 2007 Q3 | -6.12 Million USD | 3.14% |
| 2007 FY | - USD | -8.92% |
| 2007 Q1 | -5.02 Million USD | 21.94% |
| 2007 Q2 | -6.32 Million USD | -25.91% |
| 2006 FY | - USD | -43.75% |
| 2006 Q4 | -6.43 Million USD | -49.47% |
| 2006 Q3 | -4.3 Million USD | 30.34% |
| 2006 Q2 | -6.18 Million USD | -58.69% |
| 2006 Q1 | -3.89 Million USD | 1.99% |
| 2005 Q1 | -2.18 Million USD | 4.5% |
| 2005 Q3 | -4.05 Million USD | -21.78% |
| 2005 Q4 | -3.97 Million USD | 2.04% |
| 2005 FY | - USD | -29.91% |
| 2005 Q2 | -3.33 Million USD | -52.4% |
| 2004 Q1 | -2.17 Million USD | 35.99% |
| 2004 FY | - USD | -11.82% |
| 2004 Q4 | -2.29 Million USD | 27.35% |
| 2004 Q3 | -3.15 Million USD | -8.2% |
| 2004 Q2 | -2.91 Million USD | -34.05% |
| 2003 Q1 | -1.4 Million USD | 41.65% |
| 2003 Q3 | -3.2 Million USD | -98.08% |
| 2003 Q2 | -1.61 Million USD | -15.24% |
| 2003 FY | - USD | 27.88% |
| 2003 Q4 | -2.43 Million USD | -5.93% |
| 2002 Q3 | -1.6 Million USD | 40.74% |
| 2002 Q1 | -5.41 Million USD | -274.4% |
| 2002 FY | - USD | -401.09% |
| 2002 Q4 | -2.35 Million USD | -47.99% |
| 2002 Q2 | -2.74 Million USD | 59.29% |
| 2001 Q4 | 3.86 Million USD | 298.81% |
| 2001 Q1 | -2.26 Million USD | 26.06% |
| 2001 Q3 | -1.94 Million USD | 29.1% |
| 2001 Q2 | -3.19 Million USD | -26.77% |
| 2001 FY | - USD | 75.98% |
| 2000 Q4 | -2.92 Million USD | -4.96% |
| 2000 Q2 | -2.08 Million USD | 37.69% |
| 2000 FY | - USD | 4.95% |
| 2000 Q1 | -3.34 Million USD | -0.75% |
| 2000 Q3 | -2.78 Million USD | -33.8% |
| 1999 Q3 | -3.49 Million USD | -25.93% |
| 1999 Q2 | -2.7 Million USD | -3.85% |
| 1999 Q1 | -2.29 Million USD | 39.53% |
| 1999 FY | - USD | 23.41% |
| 1999 Q4 | -3.31 Million USD | 2.41% |
| 1998 Q3 | -3.8 Million USD | -16.22% |
| 1998 Q4 | -3.9 Million USD | 0.0% |
| 1998 Q1 | -2.4 Million USD | 19.44% |
| 1998 Q2 | -3.2 Million USD | -27.59% |
| 1998 FY | - USD | -23.39% |
| 1997 Q2 | -2.9 Million USD | -30.77% |
| 1997 FY | - USD | -72.22% |
| 1997 Q4 | -3.1 Million USD | -33.33% |
| 1997 Q3 | -2.1 Million USD | 20.59% |
| 1997 Q1 | -2.1 Million USD | -30.0% |
| 1996 Q1 | -1.5 Million USD | 63.41% |
| 1996 Q2 | -2 Million USD | -33.33% |
| 1996 Q3 | -1.2 Million USD | 40.0% |
| 1996 Q4 | -1.7 Million USD | -66.67% |
| 1996 FY | - USD | -63.64% |
| 1995 Q2 | -700 Thousand USD | 30.0% |
| 1995 Q4 | -4.1 Million USD | -4200.0% |
| 1995 Q3 | 100 Thousand USD | 114.29% |
| 1995 FY | - USD | -57.14% |
| 1995 Q1 | -1 Million USD | 65.52% |
| 1994 Q3 | 100 Thousand USD | 120.0% |
| 1994 Q2 | -500 Thousand USD | -600.0% |
| 1994 Q1 | 100 Thousand USD | 116.67% |
| 1994 FY | - USD | -40.0% |
| 1994 Q4 | -2.9 Million USD | -3000.0% |
| 1993 Q1 | 100 Thousand USD | 106.25% |
| 1993 Q3 | -200 Thousand USD | -300.0% |
| 1993 Q4 | -600 Thousand USD | -200.0% |
| 1993 FY | - USD | -33.33% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| 1992 Q2 | 100 Thousand USD | 0.0% |
| 1992 Q3 | 100 Thousand USD | 0.0% |
| 1992 Q4 | -1.6 Million USD | -1700.0% |
| 1992 Q1 | 100 Thousand USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 89.919% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -20.786% |
| SQZ Biotechnologies Company | -64.14 Million USD | 88.835% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 58.772% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 107.615% |
| Mesoblast Limited | -62.38 Million USD | 88.522% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -366.214% |
| Genus plc | 73.7 Million USD | 109.717% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -8.315% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -101.897% |
| Marizyme, Inc. | -34.28 Million USD | 79.11% |
| ContraFect Corporation | -64.99 Million USD | 88.982% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 18.362% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -58.218% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -410.86% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -170.804% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -208.168% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1282.363% |
| Accustem Sciences Inc. | -3.74 Million USD | -91.15% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 85.151% |
| EV Biologics, Inc. | -1.26 Million USD | -465.156% |
| Q BioMed Inc. | -617.62 Thousand USD | -1059.48% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 300.484% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1032.386% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -213.474% |
| Biomind Labs Inc. | -1.03 Million USD | -592.212% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 172.505% |
| Skye Bioscience, Inc. | -13.54 Million USD | 47.14% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -381.459% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -28545.1% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -84.364% |
| IMV Inc. | -35.52 Million USD | 79.841% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 54.875% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -186.226% |
| GB Sciences, Inc. | -1.41 Million USD | -404.356% |
| Alpha Cognition Inc. | -9.7 Million USD | 26.215% |
| HST Global, Inc. | -5303.00 USD | -134941.957% |
| CSL Limited | 4.78 Billion USD | 100.15% |
| Halberd Corporation | -74.27 Thousand USD | -9541.049% |
| Enzolytics Inc. | -2.12 Million USD | -237.473% |
| Resverlogix Corp. | -11.74 Million USD | 39.011% |
| Affymax, Inc. | -14.29 Million USD | 49.904% |
| SYBLEU INC | -141.57 Thousand USD | -4958.434% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -133.798% |
| argenx SE | -216.02 Million USD | 96.685% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 87.059% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 688.437% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -377.767% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1990.297% |
| AVAX Technologies, Inc. | -6.11 Million USD | -17.155% |
| Zenith Capital Corp. | -8.6 Million USD | 16.787% |
| Genscript Biotech Corporation | -248.71 Million USD | 97.121% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -41007.141% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -192.72% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -3968.343% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 81.933% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -147.596% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -584.43% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 106603.198% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -309.216% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -272.806% |
| BioStem Technologies, Inc. | -7.55 Million USD | 5.194% |
| ONE Bio Corp. | 13.61 Million USD | 152.606% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -3854.583% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -248.142% |
| Agentix Corp. | -1.37 Million USD | -422.052% |
| LadRx Corporation | 412.28 Thousand USD | 1836.98% |
| Cell Source, Inc. | -4.27 Million USD | -67.612% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1850.127% |
| Regen BioPharma, Inc. | 1.46 Million USD | 588.505% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -664.319% |
| NovAccess Global Inc. | -1.03 Million USD | -592.046% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 180.884% |
| Itoco Inc. | -1.86 Million USD | -283.162% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1786.432% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -541.691% |
| Kadimastem Ltd | -2.62 Million USD | -172.875% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -2894.47% |
| CytoDyn Inc. | -18.02 Million USD | 60.279% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -8961.579% |
| Mobile Lads Corp. | -2.24 Million USD | -219.534% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -58459.776% |
| Qrons Inc. | -40.08 Thousand USD | -17767.007% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1374.49% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1457.76% |
| Rebus Holdings, Inc. | -951 Thousand USD | -653.026% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -574.313% |
| International Stem Cell Corporation | 202 Thousand USD | 3645.186% |
| Bioxytran, Inc. | -3.82 Million USD | -87.461% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -13504.246% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -190.88% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 80.035% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -15813.944% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -161.551% |
| Neutra Corp. | -181.24 Thousand USD | -3851.114% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 64.476% |
| PureTech Health plc | -11.62 Million USD | 38.408% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 64.474% |
| IXICO plc | -707 Thousand USD | -912.91% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 6.815% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 85.187% |
| CSL Limited | 4.73 Billion USD | 100.151% |
| Cellectis S.A. | -92.63 Million USD | 92.269% |